The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
 
Sonja Loges
Research Funding - BerGenBio
Travel, Accommodations, Expenses - BerGenBio
 
Björn Tore Gjertsen
No Relationships to Disclose
 
Michael Heuser
No Relationships to Disclose
 
Jörg Chromik
No Relationships to Disclose
 
Carlos Enrique Vigil
No Relationships to Disclose
 
Peter Paschka
No Relationships to Disclose
 
I Ben-Batalla
No Relationships to Disclose
 
Nuray Akyüz
No Relationships to Disclose
 
David Micklem
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
Patents, Royalties, Other Intellectual Property - BerGenBio
Other Relationship - BerGenBio
 
Anthony Brown
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
James Lorens
Employment - BerGenBio
Leadership - BerGenBio
Stock and Other Ownership Interests - BerGenBio
Research Funding - BerGenBio
Patents, Royalties, Other Intellectual Property - BerGenBio
Other Relationship - BerGenBio
 
Maxim Kebenko
No Relationships to Disclose
 
Melanie Janning
No Relationships to Disclose
 
Mascha Binder
No Relationships to Disclose
 
Walter M. Fiedler
No Relationships to Disclose
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; ARIAD; Astellas Pharma; Bio-Path Holdings, Inc; BiolineRx; Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Sun Pharma (Inst); Teva (Inst)